

Ian C. Read

Chairman and Chief Executive Officer
2010–2018



SHAREHOLDER VALUE CREATED

 **\$120B+** Direct return of capital to shareholders

 **250%** Total Shareholder Return PFE
S&P 500 +180% / DRG +154%

PIPELINE STRENGTHENED

 **30** FDA approvals **15** Approvals since 2017

 **25-30** Potential approvals through 2022

Disciplined Capital Allocation to Enhance Shareholder Value

 \$13.85^B Split-off of Pfizer Animal Health	 \$11.85^B Sale of infant nutrition business to Nestlé	 Acquisition of Hospira	 Acquisition of Medivation	 Acquisition of Anacor Pharmaceuticals	 Global strategic alliance struck with Merck KGaA
--	--	---	---	--	---

Instilled OWNIT! Culture Throughout the Company

 own...the business

 win...in the marketplace

 no jerks... let's discuss behaviors

 impact... results

 trust...in one another

Grew Access to Medicines through Creative Commercial Strategies and Donations

- 
International Trachoma Initiative
 - Since 2010, Pfizer has donated more than 580 million doses of Zithromax to treat trachoma, the leading cause of infectious blindness. In response, the number of people at risk of trachoma blindness worldwide has dropped to 158 million from more than 300 million in 2010
 - Pfizer has extended this donation through 2025, when it is estimated that trachoma could be successfully eliminated around the world due in large part to the commitment of Pfizer and its partners around the world
- 
Prevention of Pneumococcal Disease through the Gavi Alliance
 - Beginning in March 2010, Pfizer pledged up to 740 million doses of its Prevnar 13 (PCV 13) vaccine through 2025 at a deeply discounted price
 - Program aimed at infants and young children under the auspices of the Advance Market Commitment (AMC) via Gavi, The Vaccine Alliance
 - Since 2010, 20+ countries have introduced PCV 13 into their immunization programs
- 
Contraception for the World's Poorest Women
 - Pfizer, the Bill & Melinda Gates Foundation, and the Children's Investment Fund Foundation (CIFF) announced in 2017 a multiyear extension of their collaboration to further broaden access to Pfizer's all-in-one injectable contraceptive, Sayana Press, for women in developing countries
 - To date, more than 6.4 million units of Sayana Press have been shipped to 20 developing countries, potentially reaching more than 1.5 million women

Please see Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and its subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as its subsequent reports on Form 8-K for a discussion of risks and uncertainties associated with forward looking statements contained herein.